As Biotech M&A Activity Gingerly Rises, Regeneron Makes Moves On Checkmate

Paying $250m For Vidutolimod Developer

 
• By Ayisha Sharma
  
Checkmate's Lead Candidate Could Be Best-In-Class • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business